BIT Capital GmbH Has $1.93 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

BIT Capital GmbH raised its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 18.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 53,539 shares of the company’s stock after buying an additional 8,429 shares during the period. BIT Capital GmbH’s holdings in SpringWorks Therapeutics were worth $1,934,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of SWTX. Segall Bryant & Hamill LLC grew its position in SpringWorks Therapeutics by 43.4% during the 4th quarter. Segall Bryant & Hamill LLC now owns 193,459 shares of the company’s stock worth $6,990,000 after acquiring an additional 58,522 shares during the last quarter. Vanguard Group Inc. boosted its stake in SpringWorks Therapeutics by 6.6% in the fourth quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company’s stock worth $258,650,000 after purchasing an additional 445,593 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of SpringWorks Therapeutics during the fourth quarter worth $455,000. Teacher Retirement System of Texas increased its stake in shares of SpringWorks Therapeutics by 26.4% in the fourth quarter. Teacher Retirement System of Texas now owns 17,609 shares of the company’s stock valued at $636,000 after buying an additional 3,674 shares in the last quarter. Finally, Platinum Investment Management Ltd. bought a new position in shares of SpringWorks Therapeutics in the fourth quarter valued at about $1,694,000.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ:SWTX opened at $46.48 on Thursday. The stock has a market cap of $3.48 billion, a price-to-earnings ratio of -13.36 and a beta of 0.76. The company has a 50 day moving average of $47.48 and a 200-day moving average of $39.63. SpringWorks Therapeutics, Inc. has a one year low of $28.21 and a one year high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). The business had revenue of $61.55 million during the quarter, compared to the consensus estimate of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. Equities research analysts anticipate that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $81.00 price objective on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. Evercore ISI increased their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Guggenheim lowered their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a report on Friday, February 21st. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, SpringWorks Therapeutics presently has an average rating of “Buy” and a consensus price target of $73.20.

Insider Transactions at SpringWorks Therapeutics

In other news, insider Bhavesh Ashar sold 1,016 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $61.19, for a total value of $62,169.04. Following the completion of the sale, the insider now directly owns 62,053 shares of the company’s stock, valued at $3,797,023.07. This represents a 1.61 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $54.23, for a total transaction of $1,084,600.00. Following the transaction, the chief operating officer now directly owns 169,712 shares in the company, valued at $9,203,481.76. The trade was a 10.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 440,766 shares of company stock worth $24,402,956 in the last three months. Insiders own 7.61% of the company’s stock.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.